Originally developed in the 1970s as an anti-cancer molecule called difluoro-methyl-ornithine (DFMO), the agent failed in trials, but had the same hair loss side effect associated with other ...

As of December 2023, DFMO won approval from the US Food and Drug Administration (FDA) for high-risk neuroblastoma as a maintenance therapy, and former patient Will Lacey is now a healthy college ...